Patent ID: 9265752
Filing Date: 2016-02-23
CPC Classification: A61K,A61P

Claim Text:
1. A rotigotine-containing transdermal patch comprising a matrix layer composition, wherein the matrix layer composition comprises, on the basis of the total weight of the matrix layer composition, 79-84% by weight of a matrix mixture system and 8-11% by weight of rotigotine, wherein the matrix mixture system is formed from a combination of a first adhesive comprising an acrylate copolymer with a second adhesive comprising dimethyl silicone polymers and silicone resins, and polyvinylpyrrolidone, wherein (1) the first adhesive is present in an amount of 5-15% by weight in the matrix mixture system, (2) the second adhesive is present in an amount of 65-75% by weight in the matrix mixture system, and (3) the polyvinylpyrrolidone is present in an amount of 1-1.5% by weight in the matrix mixture system; wherein the rotigotine is in the form of the free base or a pharmaceutically acceptable salt, wherein the acrylate copolymer is copolymerized from monomer units selected from the group consisting of butyl acrylate, isooctyl acrylate, vinyl acetate, acrylamide, and α-methacrylic acid, wherein the 0-12 hour accumulative release amount of rotigotine is about 210 to about 226 μg/cm wherein the matrix layer composition further comprises at least one auxiliary selected from the group consisting of permeation enhancers and antioxidants, and wherein if the permeation enhancer is present, the permeation enhancer is present in an amount of 8-10% based on the total weight of the matrix layer composition.